Quest diagnostics launches new ad-detect™ blood test to aid in confirming alzheimer's disease

In an oral presentation at the 2025 aan annual meeting, quest scientists presented data suggesting the test can accurately assess alzheimer's disease pathology with greater than 90% sensitivity and specificity secaucus, n.j. , april 9, 2025 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to alzheimer's disease (ad) in patients with mild cognitive impairment (mci) or dementia.
DGX Ratings Summary
DGX Quant Ranking